Page last updated: 2024-09-05

tolvaptan and mozavaptan

tolvaptan has been researched along with mozavaptan in 12 studies

Compound Research Comparison

Studies
(tolvaptan)
Trials
(tolvaptan)
Recent Studies (post-2010)
(tolvaptan)
Studies
(mozavaptan)
Trials
(mozavaptan)
Recent Studies (post-2010) (mozavaptan)
967172786165824

Protein Interaction Comparison

ProteinTaxonomytolvaptan (IC50)mozavaptan (IC50)
Vasopressin V2 receptorHomo sapiens (human)0.6373
Vasopressin V1a receptorRattus norvegicus (Norway rat)3.2
Vasopressin V1a receptorHomo sapiens (human)1.1373
Vasopressin V1b receptorHomo sapiens (human)2
Vasopressin V1b receptorRattus norvegicus (Norway rat)5
Vasopressin V2 receptor Rattus norvegicus (Norway rat)0.012

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's5 (41.67)29.6817
2010's4 (33.33)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Aoyama, M; Hirano, T; Itoh, S; Kondo, K; Kotosai, K; Mori, T; Nakamura, S; Ogawa, H; Onogawa, T; Tominaga, M; Tsujimae, K; Tsujimoto, G; Yamada, Y; Yamamura, Y; Yamashita, H; Yamashita, T1
Kitano, K; Kondo, K; Miyamoto, H; Mori, T; Nakamura, S; Nakaya, K; Ogawa, H; Onogawa, T; Tanaka, M; Tominaga, M; Yamamura, Y; Yamashita, H1
Hirano, T; Itai, A; Kan, K; Kondo, K; Kurimura, M; Mori, T; Nakamura, S; Ogawa, H; Shinohara, T; Tanada, Y; Tominaga, M; Yamamura, Y; Yamashita, H1
Balding, LC; Burrell, LM; Johnston, CI; Naitoh, M; Risvanis, J1
Gattone, V; Harris, PC; Torres, VE; Wang, X1
Gross, P; Herbrig, K; Palm, C; Pistrosch, F1
Torres, VE1
Villabona, C1
Akioka, Y; Fujita, T; Hashimoto, M; Hisano, M; Igarashi, T; Iida, A; Iiri, T; Makita, N; Manaka, K; Miura, K; Sekine, T; Takahashi, K; Takubo, N; Ueda, N1
Dabrowska, MD; Krysiak, R; Okopień, B1
Iwao, H; Izumi, Y; Miura, K1
Hammond, S; Meng, X; Mosedale, M; Naisbitt, DJ1

Reviews

6 review(s) available for tolvaptan and mozavaptan

ArticleYear
Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
    Experimental physiology, 2000, Volume: 85 Spec No

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hypertension; Morpholines; Receptors, Vasopressin; Spiro Compounds; Tolvaptan

2000
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    The American journal of medicine, 2006, Volume: 119, Issue:7 Suppl 1

    Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins

2006
Role of vasopressin antagonists.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Fluids; Cell Proliferation; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Treatment Outcome

2008
[Vasopressin receptor antagonists: the vaptans].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57 Suppl 2

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins

2010
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012, Volume: 65, Issue:1

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan

2012
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Journal of pharmacological sciences, 2014, Volume: 124, Issue:1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling

2014

Other Studies

6 other study(ies) available for tolvaptan and mozavaptan

ArticleYear
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    The Journal of pharmacology and experimental therapeutics, 1998, Volume: 287, Issue:3

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Urea Nitrogen; Creatinine; Diuretics; Dose-Response Relationship, Drug; HeLa Cells; Humans; Male; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Sodium; Tolvaptan; Transfection

1998
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Bioorganic & medicinal chemistry, 1999, Volume: 7, Issue:8

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Tolvaptan

1999
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
    Journal of medicinal chemistry, 2000, Nov-16, Volume: 43, Issue:23

    Topics: Administration, Oral; Animals; Arginine Vasopressin; Benzazepines; Cyclic AMP; Diuresis; Drug Design; Female; HeLa Cells; Humans; Models, Molecular; Molecular Conformation; Radioligand Assay; Rats; Receptors, Vasopressin; Structure-Activity Relationship

2000
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:4

    Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan

2005
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    The Journal of biological chemistry, 2012, Jan-13, Volume: 287, Issue:3

    Topics: Amino Acid Substitution; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Membrane; Child; Child, Preschool; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Humans; Male; Mutation, Missense; Neurophysins; Protein Precursors; Receptors, Vasopressin; Tolvaptan; Vasopressins

2012
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan.
    Toxicology letters, 2023, Jan-15, Volume: 373

    Topics: Antidiuretic Hormone Receptor Antagonists; Clone Cells; Humans; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan

2023